市場調查報告書

中樞神經系統 (CNS) 淋巴瘤的全球市場:預後的種類·診斷的種類·治療的種類·各用途的未來預測

CNS Lymphoma Market - Forecast (2020 - 2025)

出版商 IndustryARC 商品編碼 416591
出版日期 內容資訊 英文 104 Pages
商品交期: 2-3個工作天內
價格
中樞神經系統 (CNS) 淋巴瘤的全球市場:預後的種類·診斷的種類·治療的種類·各用途的未來預測 CNS Lymphoma Market - Forecast (2020 - 2025)
出版日期: 2020年03月11日內容資訊: 英文 104 Pages
簡介

本報告提供全球中樞神經系統 (CNS) 淋巴瘤的市場相關分析,提供整體市場結構和背景情況,主要的推動及阻礙市場要素,預後/診斷/治療類別及地區別的市場趨勢預測,市場競爭情勢,近來的資本交易·策略發展的動向,主要企業的簡介等相關調查。

第1章 市場概要

第2章 摘要整理

第3章 中樞神經系統 (CNS) 淋巴瘤市場:市場環境

  • 市場佔有率分析
  • 競爭分析
    • 終端用戶的簡介
    • 專利分析
    • 前五名公司的財務分析

第4章 CNS淋巴瘤市場:對市場的影響要素

  • 市場成長促進因素
  • 阻礙市場要素
  • 市場課題
  • 市場向心力:波特的五力分析

第5章 CNS淋巴瘤市場:策略分析

  • 價值鏈分析
  • 價格趨勢分析
  • 市場機會分析
  • 產品生命週期分析
  • 供應商/經銷商

第6章 CNS淋巴瘤市場:預後類別

  • 免疫響應能力
  • AIDS (後天性免疫機能喪失症候群)

第7章 CNS淋巴瘤市場:診斷類別

  • 腰椎穿刺/腦脊髓液 (CSF)的病理分析
  • 腦切片檢查樣品採取
  • MRI (核磁共振成像)
  • CT (電腦斷層攝影) 掃描
  • 定位切片檢查
  • 血液常規檢查 (CBC)
  • 其他

第8章 CNS淋巴瘤市場:治療類別

  • 放射治療
  • 化療
  • 類固醇治療
  • 大量化療 (附幹細胞移植)
  • 標靶治療
  • 其他

第9章 CNS淋巴瘤市場:各地區

  • 北美 (美國,加拿大等)
  • 歐洲 (英國,德國,法國,西班牙,義大利等)
  • 亞太地區 (中國,印度,日本,澳洲等)
  • 南美 (巴西,阿根廷,墨西哥等)
  • 其他的國家 (RoW:中東,非洲)

第10章 CNS淋巴瘤市場:市場熵 (市場變化的方向性)

  • 新產品的銷售
  • 企業合併·收購 (M&A),事業聯盟·合作,合資企業 (JV)

第11章 企業簡介 (概要,財務分析,主要產品與服務,近幾年趨勢,競爭企業,客戶)

  • Brainstrust
  • Brain and Spine Foundation
  • Headway
  • Royal National Institute for the Blind (RNIB)
  • Carers UK
  • Cancer Research UK
  • American Brain Tumor Association
  • Leukaemia Foundation
  • Macmillan Cancer Support
  • Center for Lymphoid Malignancies

第12章 附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: HCR 0124

Central Nervous System (CNS) Lymphoma or microglioma is a disease in which cancer cells are formed in the lymph tissue of the brain or spinal cord. This is observed primarily in patients with very weak immune systems, patients suffering from immunosuppression, and AIDS patients. Patients who have undergone recent kidney or other organ transplants are also at a high risk of having CNS lymphoma due to their low count of T-Cells or low level of immunity. The major symptoms of this disease include headaches, memory problem, drowsiness, seizures, nausea, vomiting, personality changes, throat infection, body weakness, and sometimes, even hearing loss and double vision. This disease may occur in all age groups; however, it is mostly noticed in people in the 50+ age group. The global central nervous system lymphoma market is estimated to surpass $1,127m by 2023, growing at an estimated CAGR of 6.65% from 2018 to 2023. The North America region is the largest market for CNS lymphoma.

CNS Lymphoma Market Outlook

The report covers the major diagnosis methods including lumber puncture, pathological analysis of cerebrospinal fluid (CSF), brain biopsy sampling, magnetic resonance imaging (MRI), computed topography (CT) scan, stereostatic biopsy, and complete blood count. The market is further categorized by prognosis types, which include Immunocompetent and AIDS. Based on treatment types, the market is segmented into radiation therapy, chemotherapy, steroid therapy, targeted therapy, and others.

CNS Lymphoma Market Growth Drivers

The market is expected to be majorly driven by the rising prevalence of primary CNS lymphoma, increasing awareness regarding the advanced technologies in the market, and rising governmental spending on healthcare. The demand for diagnostic methods is on the surge; thus, propelling the demand for CNS lymphoma treatment across the regions.

CNS Lymphoma Market Challenges

Stringent regulations imposed on drugs by the regulatory bodies coupled with the rising R&D costs pose major challenges for the CNS lymphoma market. Owing to the intake of drug, chances of occurrence of side effects such as fatigue, gastrointestinal complication, graft versus host disease, and late effects of cancer survivors will negatively impact the growth of the market.

CNS Lymphoma Market

CNS Lymphoma Assembly Market Research Scope

The base year of the study is 2017, with forecast done up to 2023. The study presents a thorough analysis of the competitive landscape, taking into account the market shares of the leading companies. It also provides information on unit shipments. These provide the key market participants with the necessary business intelligence and help them understand the future of the CNS lymphoma market. The assessment includes the forecast, an overview of the competitive structure, the market shares of the competitors, as well as the market trends, market demands, market drivers, market challenges, and product analysis. The market drivers and restraints have been assessed to fathom their impact over the forecast period. This report further identifies the key opportunities for growth while also detailing the key challenges and possible threats. The key areas of focus include the types of prognosis and diagnosis in the CNS Lymphoma market, and their treatment methods.

CNS Lymphoma Market Report: Industry Coverage

Prognosis in CNS Lymphoma Market: Immunocompetent and AIDS

Diagnosis in CNS Lymphoma Market: Lumbar Puncture/Pathological Analysis of Cerebrospinal Fluid (CSF), Brain Biopsy Sampling and Stereotactic Biopsy, Magnetic Resonance Imaging (MRI), Computed Topography (CT scan), Complete Blood Count, and Others

Treatment in CNS Lymphoma Market: Radiation Therapy, Chemotherapy, Steroid Therapy, and Others

The CNS lymphoma Market report also analyzes the major geographic regions for the market as well as the major countries for the market in these regions. The regions and countries covered in the study include:

North America: The U.S., Canada, Mexico

Europe: The U.K., Germany, Italy, France, Spain, Rest of Europe

APAC: China, Japan, Australia & New Zealand, South Korea, India, Rest of APAC

RoW: The Middle East, Africa, South America

CNS Lymphoma Market Key Players Perspective

Some of the key players mentioned in this report are Amgen Inc., Celegene Corp., Cipla Inc., Dr. Reddy's Laboratories, F. Hoffmann-La Roche Ltd., Fresenius SE & CO. KGAA, Gilead Science, Inc., Johnson & Johnson, Merck & CO., Inc., and Sanofi S.A.

CNS Lymphoma Market Trends

Increased investments in healthcare, and research and development

Growing prevalence of primary CNS lymphoma, and increasing awareness about advanced technologies in the market

Advancements in MRI and CT scan technology coupled with increasing healthcare expenditure are driving the growth of the market.

Diagnosis methods such as Magnetic Resonance Imaging (MRI) accounted for the major share of the total market in 2017. As per IndustryARC analysis, the chemotherapy segment will generate healthy revenue by 2023.

1. CNS Lymphoma Market - Overview

  • 1.1. Definitions and Scope

2. CNS Lymphoma Market - Executive summary

  • 2.1. Market Revenue, Market Size and Key Trends by Company
  • 2.2. Key Trends by type of Application
  • 2.3. Key Trends segmented by Geography

3. CNS Lymphoma Market

  • 3.1. Comparative analysis
    • 3.1.1. Product Benchmarking - Top 10 companies
    • 3.1.2. Top 5 Financials Analysis
    • 3.1.3. Market Value split by Top 10 companies
    • 3.1.4. Patent Analysis - Top 10 companies
    • 3.1.5. Pricing Analysis

4. CNS Lymphoma Market Forces

  • 4.1. Drivers
  • 4.2. Constraints
  • 4.3. Challenges
  • 4.4. Porters five force model
    • 4.4.1. Bargaining power of suppliers
    • 4.4.2. Bargaining powers of customers
    • 4.4.3. Threat of new entrants
    • 4.4.4. Rivalry among existing players
    • 4.4.5. Threat of substitutes

5. CNS Lymphoma Market -Strategic analysis

  • 5.1. Value chain analysis
  • 5.2. Opportunities analysis
  • 5.3. Product life cycle
  • 5.4. Suppliers and distributors Market Share

6. CNS Lymphoma Market - By Prognosis Type (Market Size -$Million / $Billion)

  • 6.1. Market Size and Market Share Analysis
  • 6.2. Application Revenue and Trend Research
  • 6.3. Product Segment Analysis
    • 6.3.1. Immunocompetent
    • 6.3.2. AIDS

7. CNS Lymphoma Market - By Type of Diagnosis (Market Size -$Million / $Billion)

  • 7.1. Introduction
  • 7.2. Lumbar Puncture/Pathological Analysis of cerebrospinal fluid (CSF)
  • 7.3. Brain biopsy sampling
  • 7.4. MRI (Magnetic Resonance Imaging)
  • 7.5. CT Scan (Computed Tomography)
  • 7.6. Stereotactic Biopsy
  • 7.7. Complete Blood Count
  • 7.8. Others

8. CNS Lymphoma Market - By Type of Treatment (Market Size -$Million / $Billion)

  • 8.1. Introduction
  • 8.2. Radiation Therapy
  • 8.3. Chemotherapy
  • 8.4. Steroid Therapy
  • 8.5. Targeted Therapy
  • 8.6. Others

9. CNS Lymphoma - By Geography (Market Size -$Million / $Billion)

  • 9.1. CNS Lymphoma Market - North America Segment Research
  • 9.2. North America Market Research (Million / $Billion)
    • 9.2.1. Segment type Size and Market Size Analysis
    • 9.2.2. Revenue and Trends
    • 9.2.3. Application Revenue and Trends by type of Application
    • 9.2.4. Company Revenue and Product Analysis
    • 9.2.5. North America Product type and Application Market Size
      • 9.2.5.1. U.S.
      • 9.2.5.2. Canada
      • 9.2.5.3. Mexico
      • 9.2.5.4. Rest of North America
  • 9.3. CNS Lymphoma - South America Segment Research
  • 9.4. South America Market Research (Market Size -$Million / $Billion)
    • 9.4.1. Segment type Size and Market Size Analysis
    • 9.4.2. Revenue and Trends
    • 9.4.3. Application Revenue and Trends by type of Application
    • 9.4.4. Company Revenue and Product Analysis
    • 9.4.5. South America Product type and Application Market Size
      • 9.4.5.1. Brazil
      • 9.4.5.2. Venezuela
      • 9.4.5.3. Argentina
      • 9.4.5.4. Ecuador
      • 9.4.5.5. Peru
      • 9.4.5.6. Colombia
      • 9.4.5.7. Costa Rica
      • 9.4.5.8. Rest of South America
  • 9.5. CNS Lymphoma - Europe Segment Research
  • 9.6. Europe Market Research (Market Size -$Million / $Billion)
    • 9.6.1. Segment type Size and Market Size Analysis
    • 9.6.2. Revenue and Trends
    • 9.6.3. Application Revenue and Trends by type of Application
    • 9.6.4. Company Revenue and Product Analysis
    • 9.6.5. Europe Segment Product type and Application Market Size
      • 9.6.5.1. U.K
      • 9.6.5.2. Germany
      • 9.6.5.3. Italy
      • 9.6.5.4. France
      • 9.6.5.5. Netherlands
      • 9.6.5.6. Belgium
      • 9.6.5.7. Spain
      • 9.6.5.8. Denmark
      • 9.6.5.9. Rest of Europe
  • 9.7. CNS Lymphoma - APAC Segment Research
  • 9.8. APAC Market Research (Market Size -$Million / $Billion)
    • 9.8.1. Segment type Size and Market Size Analysis
    • 9.8.2. Revenue and Trends
    • 9.8.3. Application Revenue and Trends by type of Application
    • 9.8.4. Company Revenue and Product Analysis
    • 9.8.5. APAC Segment - Product type and Application Market Size
      • 9.8.5.1. China
      • 9.8.5.2. Australia
      • 9.8.5.3. Japan
      • 9.8.5.4. South Korea
      • 9.8.5.5. India
      • 9.8.5.6. Taiwan
      • 9.8.5.7. Malaysia

10. CNS Lymphoma Market - Entropy

  • 10.1. New product launches
  • 10.2. M&A's, collaborations, JVs and partnerships

11. CNS Lymphoma Market Company Analysis

  • 11.1. Market Share, Company Revenue, Products, M&A, Developments
  • 11.2. Amgen Inc.
  • 11.3. Celegene Corp.
  • 11.4. Cipla Inc.
  • 11.5. Dr. Reddy's Laboratories
  • 11.6. F. Hoffmann-La Roche Ltd.
  • 11.7. Fresenius SE & CO. KGAA
  • 11.8. Gilead Science Inc.
  • 11.9. Johnson & Johnson
  • 11.10. Merck & CO., Inc.,
  • 11.11. Company 10
  • 11.12. Company 11
  • 11.13. Company 12 and more

"*Financials would be provided on a best efforts basis for private companies"

12. CNS Lymphoma Market -Appendix

  • 12.1. Abbreviations
  • 12.2. Sources